{
    "clinical_study": {
        "@rank": "146366", 
        "acronym": "STEADFAST", 
        "arm_group": {
            "arm_group_label": "Telaprevir and Sofosbuvir", 
            "arm_group_type": "Experimental", 
            "description": "All subjects will receive Telaprevir twice a day, 1125mg capsule and Sofosbuvir 400 mg capsule once daily.  Both will be given for 12 weeks."
        }, 
        "brief_summary": {
            "textblock": "This is an open-label, multi center study of treatment-naive non-cirrhotic subjects with\n      genotype 1 chronic Hepatitis C Virus.  All subjects will receive telaprevir (TVR) in\n      combination with sofosbuvir (SOF) for 12 weeks."
        }, 
        "brief_title": "Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Starting on Day 1 and for up to 12 weeks, you will receive Telaprevir (TVR) and Sofosbuvir\n      (SOF).\n\n      You will take one (1) 400 mg tablet of SOF and 3 tablets (1125 mg each) of TVR.  You should\n      take these together by mouth every morning. You will take another 3 tablets (1125 mg each)\n      of TVR by mouth 12 hours after you take your morning dose."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Willing and able to provide informed consent\n\n          -  BMI (Body Mass Index) \u2265 18 kg/m2\n\n          -  HCV RNA quantifiable at screening and  >1,000 IU/ml\n\n          -  HCV treatment Na\u00efve\n\n          -  HCV genotype 1\n\n          -  7. Confirmation of chronic HCV infection documented by either: A positive anti-HCV\n             antibody test or positive HCV RNA or positive HCV genotyping test at least 6 months\n             prior to the Baseline/Day 1 visit, or A liver biopsy performed prior to the\n             Baseline/Day 1 visit with evidence of chronic HCV infection\n\n        Exclusion Criteria:\n\n          -  Current or prior history of any of the following:\n\n        Clinically-significant illness Cirrhosis 2. Screening ECG with clinically significant\n        abnormalities\n\n          1. ALT > 10 x the upper limit of normal (ULN)\n\n          2. AST > 10 x ULN\n\n          3. Direct bilirubin > 1.5 x ULN\n\n          4. Platelets < 150,000/\u03bcL\n\n          5. HbA1c > 7.5%\n\n          6. Creatinine clearance (CLcr) < 60 mL /min, as calculated by the Cockcroft-Gault\n             equation\n\n          7. Hemoglobin < 11 g/dL for female subjects; < 12 g/dL for male subjects.\n\n          8. Albumin < 3.1 g/dL\n\n          9. INR > 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant\n             regimen affecting INR 4. Prior exposure to any approved or experimental HCV-specific\n             direct-acting\n\n             5. Pregnant or nursing female or male with pregnant female partner.\n\n             6. Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's\n             disease, alfa-1 antitrypsin deficiency, cholangitis).\n\n             7. Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01994486", 
            "org_study_id": "20132125"
        }, 
        "intervention": {
            "arm_group_label": "Telaprevir and Sofosbuvir", 
            "description": "All subjects will have an ECG performed.  Then they will receive Telaprevir twice a day, 1125mg capsule and Sofosbuvir 400 mg capsule once daily. Both will be given for 12 weeks.  In addition, PK samples will be collected at week 2 and week 10.", 
            "intervention_name": "Telaprevir and Sofosbuvir", 
            "intervention_type": "Drug", 
            "other_name": [
                "TVR", 
                "SOF"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "HCV Genotype 1", 
            "Hepatitis C Virus Genotype 1", 
            "HCV", 
            "TVR"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gainesville", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32610"
                }, 
                "name": "UF Hepatology Research at CTRB"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Open-Label Study to Evaluate the Safety and Tolerability of Telaprevir in Combination With Sofosbuvir in Treatment Naive Subjects Chronically Infected With Hepatitis C Virus Genotype 1", 
        "other_outcome": {
            "description": "Assessment of the antiviral efficacy (SVR 12) of combination treatment with telaprevir and sofosbuvir administered for 12 weeks.", 
            "measure": "Number of subjects with Sustained Virologic Response", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "overall_official": {
            "affiliation": "University of Florida", 
            "last_name": "DAVID R NELSON, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Frequency of adverse events among subjects treated with Telaprevir and Sofosbuvir", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01994486"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Sparse PK will be collected at Week 2 and Week 10", 
            "measure": "Minimum plasma concentration of Telaprevir in patients treated with Telaprevir and Sofosbuvir", 
            "safety_issue": "No", 
            "time_frame": "Week 2 and Week 10"
        }, 
        "source": "University of Florida", 
        "sponsors": {
            "collaborator": {
                "agency": "Vertex Pharmaceuticals Incorporated", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Florida", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}